Utama › Limfoma Burkitt
Kajian klinikal Limfoma Burkitt sedang mengambil peserta di AS
63 kajian untuk Limfoma Burkitt sedang mengambil peserta di lokasi seluruh Amerika Syarikat.
Bandar dengan paling banyak kajian
- Houston, TX21 kajian
- Milwaukee, WI16 kajian
- Philadelphia, PA16 kajian
- New York City, NY14 kajian
- Chicago, IL14 kajian
- Cincinnati, OH12 kajian
- Atlanta, GA12 kajian
- Seattle, WA11 kajian
- Boston, MA10 kajian
- Durham, NC10 kajian
- Kansas City, MO10 kajian
- Los Angeles, CA10 kajian
- Aurora, CO10 kajian
- Orange, CA9 kajian
- Minneapolis, MN9 kajian
- Washington, DC9 kajian
- Baldwin Park, CA9 kajian
- Buffalo, NY8 kajian
- Columbus, OH8 kajian
- Portland, OR8 kajian
- Baltimore, MD8 kajian
- San Francisco, CA8 kajian
- Nashville, TN8 kajian
- Ann Arbor, MI8 kajian
- Tampa, FL7 kajian
- Dallas, TX7 kajian
- Clifton, NJ7 kajian
- Providence, RI7 kajian
- Jacksonville, FL7 kajian
- Greenburgh, NY7 kajian
- Birmingham, AL7 kajian
- Richmond, VA7 kajian
- Cleveland, OH7 kajian
- San Antonio, TX7 kajian
- Grand Rapids, MI7 kajian
- Salt Lake City, UT7 kajian
- Oklahoma City, OK7 kajian
- The Bronx, NY6 kajian
- Mountain View, CA6 kajian
- Cicero, IL6 kajian
Mengikut negeri
- Alabama7 kajian
- Arizona7 kajian
- Arkansas5 kajian
- California20 kajian
- Colorado13 kajian
- Connecticut7 kajian
- Delaware7 kajian
- Florida15 kajian
- Georgia12 kajian
- Hawaii5 kajian
- Idaho6 kajian
- Illinois14 kajian
- Indiana6 kajian
- Iowa7 kajian
- Kansas6 kajian
- Kentucky5 kajian
- Louisiana4 kajian
- Maine4 kajian
- Maryland11 kajian
- Massachusetts10 kajian
- Michigan10 kajian
- Minnesota10 kajian
- Mississippi4 kajian
- Missouri8 kajian
- Nebraska5 kajian
- Nevada6 kajian
- New Hampshire4 kajian
- New Jersey8 kajian
- New Mexico3 kajian
- New York20 kajian
- North Carolina13 kajian
- North Dakota5 kajian
- Ohio17 kajian
- Oklahoma7 kajian
- Oregon8 kajian
- Pennsylvania18 kajian
- Rhode Island7 kajian
- South Carolina5 kajian
- South Dakota5 kajian
- Tennessee10 kajian
- Texas24 kajian
- Utah7 kajian
- Vermont3 kajian
- Virginia7 kajian
- Washington11 kajian
- West Virginia3 kajian
- Wilayah Columbia5 kajian
- Wisconsin17 kajian
Kajian yang dikemas kini baru-baru ini
Teks kajian rasmi (Bahasa Inggeris)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Mengambil pesertaFasa 2
366 Days – 46 Years · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Mengambil pesertaFasa 3
Umur 18 hingga 39 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT03150693Blinatumomab Consolidation in Real World
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07117136Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Mengambil pesertaKajian pemerhatian
Umur 0 hingga 38 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Mengambil pesertaFasa 1/2
Umur 3 hingga 39 · Semua jantina · Dikemas kini 30 Sep 2026 · NCT05442515Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT03739814Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Mengambil pesertaFasa 1/2
Umur 18 hingga 120 · Semua jantina · Dikemas kini 28 Sep 2026 · NCT03223610Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06144606Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Mengambil pesertaFasa 2
365 Days · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Mengambil pesertaFasa 3
Umur 1 ke atas · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Mengambil pesertaFasa 1/2
6 Months – 25 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Mengambil pesertaFasa 1
Umur 0 hingga 18 · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06173518UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
Mengambil pesertaFasa 1/2
31 Days – 30 Years · Semua jantina · Dikemas kini 14 Sep 2026 · NCT04544592Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Mengambil pesertaFasa 2
Umur 1 hingga 30 · Semua jantina · Dikemas kini 1 Sep 2026 · NCT04546399Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Mengambil pesertaFasa 1
Umur 18 hingga 120 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05389423Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Mengambil pesertaFasa 3
365 Days – 25 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03959085Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT06710418Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Mengambil pesertaFasa 2
Umur 7 hingga 25 · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT06137118AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT06340737Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT06287229Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Mengambil pesertaFasa 2
Umur 15 ke atas · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT03136146Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Mengambil pesertaFasa 1/2
Umur 13 hingga 90 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06533579Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.